ŌNŌCOR has entered an exclusive distribution agreement with B. Braun Interventional Systems (BIS) for its ŌNŌ retrieval device in the US.
As part of the agreement, BIS will begin commercialisation activities for the device in the country.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The ŌNŌ device is intended to receive, align, compress and remove material (non-biologic and biologic) from the vascular system.
It is also compatible with commercially available endovascular snares, vascular sheaths and other graspers.
The device has been designed to reduce the need for remedial surgical procedures, as well as make catheter-based retrieval less tedious, quicker and safer.
BIS upstream marketing and portfolio strategy director Peter Flosdorf said: “The ŌNŌ pushes the boundaries of how we can serve the needs of congenital and structural heart interventional cardiologists and the patients they treat.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataŌNŌCOR received clearance from the US Food and Drug Administration for the device in May 2022.
The device has since been utilised at select labs in the country.
The teams from both companies now plan a limited launch of the device later this year and the complete launch is planned for the PICS Society Annual Symposium next month.
ŌNŌCOR CEO Mark Piper said: “We are thrilled to have entered an agreement with BIS that will allow every interventionalist performing a catheter-based procedure to have an ŌNŌ device at hand.”
